About: A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 19 June 2007

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 2007 (uk) im Juni 2007 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 19 June 2007 (en) artículu científicu espublizáu en xunu de 2007 (ast)
publication date	wds:Q80500352-89857833-11F1-45EB-A0E6-D093E96D1544
publication date	2007-06-19 00:00:00Z (xsd:dateTime)
author name string	wds:Q80500352-14F94A74-7F52-4772-B6D0-DDED872DE7E5 wds:Q80500352-22D92DEB-517A-4291-A217-3FBD0D6C9EFD wds:Q80500352-2D6348AF-7F51-4E43-A4F5-094730717605 wds:Q80500352-52146F97-F5C2-447E-A596-02E074745287 wds:Q80500352-5D516BD7-1A96-452F-8450-D0693C79DB48 wds:Q80500352-BD0C1317-8DE1-470F-B0A0-AA9EE92D3AD0 wds:Q80500352-EF5D575B-FFC0-4C1F-8A27-6C69C8F0879F
author name string	E E Voest B A Zonnenberg J W B de Groot T P Links M M de Vries C J M Lips P Quarles van Ufford-Mannesse
rdfs:label	A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma (en) A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma (nl)
skos:prefLabel	A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma (en) A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma (nl)
name	A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma (en) A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma (nl)
title	wds:Q80500352-E50B472E-9067-42AB-9651-09CB9AC31039
title	A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma (en)
page(s)	wds:Q80500352-293C50E2-B6BE-476D-B587-2C1EBF0AFC86
page(s)	3466-3469
instance of	wds:Q80500352-91979C6C-C4C6-4901-BE9A-560D41AC5194
instance of	scholarly article
main subject	wds:Q80500352-D61ECB33-A8A8-4270-94FD-8AE95CC7DD3F wds:Q80500352-E91D487B-17BA-4604-B260-F8B6FDA71D9E wds:Q80500352-F2153EF2-7125-402F-913A-191381A67BB8
main subject	wd:Q177094 thyroid carcinoma phase II clinical trial
PubMed ID	wds:Q80500352-826FA385-0FE2-4CEF-8ED4-BF1D8AB489B0
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17579194
PubMed ID	17579194
published in	wds:Q80500352-D3123833-3AB4-4152-93CB-BED764969E57
published in	The Journal of Clinical Endocrinology and Metabolism
issue	wds:Q80500352-F2E3259D-FC14-4EBA-A3CD-569408FEDE23
volume	wds:Q80500352-44143DC1-71C8-48C1-A288-5F3E2F99DE9B
issue	9
volume	92
DOI	wds:Q80500352-430B8EB6-617D-42B5-B7CC-A46C848EA949
DOI	http://dx.doi.org/10.1210/JC.2007-0649
DOI	10.1210/JC.2007-0649
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q80500352
is cites work of	Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update Cabozantinib in progressive medullary thyroid cancer Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma New therapeutic approaches to treat medullary thyroid carcinoma Novel molecular targeted therapies for refractory thyroid cancer New targeted therapies for thyroid cancer Kinase inhibitors for advanced medullary thyroid carcinoma New developments in the diagnosis and treatment of thyroid cancer RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer Current understanding and management of medullary thyroid cancer New drugs for medullary thyroid cancer: new promises? Medical management of metastatic medullary thyroid cancer Update: the status of clinical trials with kinase inhibitors in thyroid cancer Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma Thyroid cancer: pathogenesis and targeted therapy New therapies for dedifferentiated papillary thyroid cancer Anti-tumor activity of motesanib in a medullary thyroid cancer model Management of advanced medullary thyroid cancer Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression. Advanced medullary thyroid cancer: pathophysiology and management Long-Term Follow-up in Medullary Thyroid Carcinoma Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer Novel targeted therapies and immunotherapy for advanced thyroid cancers. RET TKI: potential role in thyroid cancers. Levothyroxine therapy and imatinib Targeted Therapy for Medullary Thyroid Cancer: A Review. Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice Endocrine side effects of broad-acting kinase inhibitors Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma Improvement of radioimmunotherapy using pretargeting Thyroid cancer: emerging role for targeted therapies Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer. Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies Personalization of targeted therapy in advanced thyroid cancer Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers Pharmacotherapy options for advanced thyroid cancer: a systematic review Cabozantinib for progressive metastatic medullary thyroid cancer: a review Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases Angiogenesis-inhibitors for metastatic thyroid cancer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software